Anne Hollingsworth, DO
Internal Medicine · Chesterton, INNPI 1902891542
Payments from drug & device makers
Across 212 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$982
- Pfizer$361
- Novartis$308
- Lilly USA, LLC$293
- Novo Nordisk$289
- Bayer$192
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,545100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 67 | $982 |
| Pfizer | 19 | $361 |
| Novartis | 16 | $308 |
| Lilly USA, LLC | 17 | $293 |
| Novo Nordisk | 19 | $289 |
| Bayer | 9 | $192 |
| GSK | 11 | $163 |
| AstraZeneca | 8 | $144 |
| Astellas Pharma US Inc | 6 | $119 |
| Amgen | 4 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Biohaven Pharmaceuticals, Inc. | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 3 | $42 |
| Exact Sciences | 2 | $39 |
| IBSA Pharma Inc. | 3 | $39 |
| Boehringer Ingelheim | 2 | $36 |
| Dexcom, Inc. | 2 | $36 |
| Insulet Corporation | 2 | $33 |
| Johnson & Johnson | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Radius Health, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Itamar Medical Inc | 1 | $12 |
How this compares
$3,545 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $108,336 |
| TrulicityDulaglutide | 54 | $84,901 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $68,029 |
| JardianceEmpagliflozin | 51 | $57,166 |
| XareltoRivaroxaban | 40 | $50,980 |
| OzempicSemaglutide | 34 | $42,842 |
| Teriparatide | 14 | $31,983 |
| MounjaroTirzepatide | 26 | $27,644 |
| FarxigaDapagliflozin Propanediol | 34 | $23,992 |
| EntrestoSacubitril/Valsartan | 15 | $18,067 |
| JanuviaSitagliptin Phosphate | 11 | $17,885 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $16,420 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $15,299 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $12,586 |
| KerendiaFinerenone | 11 | $9,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $293 | $112,54480 claims |
| PfizerEliquis | $361 | $108,33696 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $163 | $84,44980 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $36 | $62,68663 claims |
| Johnson & JohnsonXarelto | $30 | $50,98040 claims |
| Novo NordiskOzempic | $289 | $42,84234 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $144 | $39,29146 claims |
| NovartisEntresto | $308 | $18,06715 claims |
| BayerKerendia | $192 | $9,56911 claims |
| Astellas Pharma US IncMyrbetriq | $119 | $9,32516 claims |
| AbbVieSynthroid | $982 | $3,93565 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Chesterton
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.